Value proposition

In December 2022, Integrated DNA Technologies, Inc. (IDT) announced the acquisition of ArcherTM. The integration of IDT’s portfolio with the acquired NGS research assays—powered by Anchored Multiplex PCR (AMPTM) technology, which has been foundational in researching novel cancer fusions—will empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries. The transaction enables IDT to expand its existing operations, build upon the legacy Archer portfolio, and welcome more than 100 new associates globally.

For the latest on IDT, follow their LinkedIn page here: https://www.linkedin.com/company/integrated-dna-technologies

next-generation sequencing, cancer research, ngs assays, and DNA sequencing assays